(Aβ) fibrillogenesis. With the aim of discovering novel AChE dual binders with improved drug-likeness, homo- and heterodimers containing 2H-chromen-2-one building blocks were developed. By exploring diverse linkages of neutral and protonatable amino moieties through aliphatic spacers of different length, a nanomolar bivalent AChE inhibitor was identified (3-[2-(4-[(dimethylamino)methyl]-2-oxo-2H-c
乙酰胆碱酯酶(AChE)
抑制剂仍然构成阿尔茨海默氏病(AD)的大部分市售药物。该酶的结构安排具有狭窄的峡谷,可将催化和周围的阴离子亚位点分开(分别为CAS和PAS),这激发了能够结合和阻断CAS催化活性的二价
配体的发展。 PAS在β淀粉样蛋白(Aβ)原纤维形成中的作用。为了发现具有改善的药物样的新型AChE双结合剂,开发了含有
2H-色烯-2-酮结构单元的同型和异型二聚体。通过探索不同长度的脂肪族间隔基对中性和质子化
氨基部分的各种联系,纳摩尔二价AChE
抑制剂被确定(3- [2-(4-[((二甲基
氨基)甲基] -2-氧代-2H-chromen-7-基}氧基)乙氧基] -6,7-二甲氧基-2H-chromen最初弱活性片段的-2--1(6 d),IC50 = 59 nm)。为了评估抗AD的潜力,研究了6天与疾病相关的
生物学特性。它执行混合型AChE酶动力学(抑制常数Ki = 68 nm),并